WilmerHale Receives 2013 LMG Life Sciences “Canadian Impact Deals of the Year” Award

  • 9.26.2013

On September 25, WilmerHale was named as the winner of the LMG Life Sciences "Canadian Impact Deals of the Year" award at the LMG Life Sciences Awards dinner at the Essex House in New York City. The firm was recognized for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.-a cross-border deal valued at up to $1.8 billion and led by Partners Hal Leibowitz, Belinda Juran and Jeff Hermanson.

The award was given as part of LMG's inaugural awards program that is an offshoot of the LMG Life Sciences rankings published late last spring. WilmerHale received favorable results in the guidebook, including being named for the second consecutive year as a "Lifecycle Firm" in the United States-a classification that indicates that a firm is regarded as one of the best, full-service law firms within the life sciences industry.

In addition to receiving the "Canadian Impact Deal of the Year" award at last night's event, WilmerHale had been shortlisted as a "Firm of the Year" in several categories, including: Mergers & Acquisitions, Venture Capital, Financial & Transactional, Government Investigations, Hatch-Waxman (Branded), Patent Litigation and Intellectual Property. The firm also had three individuals shortlisted for the "Attorney of the Year" award: Bill Lee (Hatch-Waxman (Branded); Intellectual Property), David Redlick (Mergers  & Acquisitions; Financial & Transactional) and Steve Singer (Corporate Advisory; Venture Capital).

The life sciences industry is a significant part of WilmerHale's practice. The firm has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for four decades. Representing public and private companies, investment banks and venture capitalists in all aspects of the life sciences industry, the firm's lawyers understand the business of these clients and the regulatory, competitive and consumer demands that the industry is currently confronting.

LMG Life Sciences' 2013 rankings and awards were developed based upon extensive industry-wide research, based on nearly 1,000 interviews and surveys completed by partners who are active in the market.